College of Medical Sciences, Bharatpur 44200, Nepal.
College of Medical Sciences, Bharatpur, Nepal.
Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241277382. doi: 10.1177/17539447241277382.
Reperfusion injury, characterized by oxidative stress and inflammation, poses a significant challenge in cardiac surgery with cardiopulmonary bypass (CPB). Deferoxamine, an iron-chelating compound, has shown promise in mitigating reperfusion injury by inhibiting iron-dependent lipid peroxidation and reactive oxygen species (ROS) production.
The objective of our study was to analyze and evaluate both the efficacy and safety of a new and promising intervention, that is, deferoxamine for ischemia-reperfusion injury (I/R).
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines are used to perform the study.
We conducted a systematic review following PRISMA guidelines to assess the efficacy and safety of deferoxamine in reducing I/R injury following CPB. A comprehensive search of electronic databases, namely, PubMed, Scopus, and Embase, yielded relevant studies published until August 18, 2023. Included studies evaluated ROS production, lipid peroxidation, cardiac performance, and morbidity outcomes.
(a) : Multiple studies demonstrated a statistically significant decrease in ROS production in patients treated with deferoxamine, highlighting its potential to reduce oxidative stress. (b) : Deferoxamine was associated with decreased lipid peroxidation levels, indicating its ability to protect cardiac tissue from oxidative damage during CPB. (c) : Some studies reported improvements in left ventricular ejection fraction and wall motion score index with deferoxamine.
Our review shows that deferoxamine is an efficacious and safe drug that can be used to prevent myocardial I/R injury following CPB. It also highlights the need for trials on a larger scale to develop potential strategies and guidelines on the use of deferoxamine for I/R injury.
再灌注损伤以氧化应激和炎症为特征，是体外循环（CPB）心脏手术面临的重大挑战。去铁胺是一种铁螯合剂，通过抑制铁依赖性脂质过氧化和活性氧（ROS）的产生，在减轻再灌注损伤方面显示出一定的效果。
本研究旨在分析和评估一种新的、有前景的干预措施，即去铁胺治疗缺血再灌注损伤（I/R）的疗效和安全性。
采用系统评价和荟萃分析（PRISMA）指南进行研究。
我们遵循 PRISMA 指南进行了系统评价，以评估 CPB 后使用去铁胺减少 I/R 损伤的疗效和安全性。全面检索了电子数据库，包括 PubMed、Scopus 和 Embase，以获取截至 2023 年 8 月 18 日发表的相关研究。纳入的研究评估了 ROS 产生、脂质过氧化、心脏功能和发病率结果。
（a）多项研究表明，接受去铁胺治疗的患者 ROS 产生显著减少，这突出了其降低氧化应激的潜力。（b）去铁胺与降低的脂质过氧化水平相关，表明其在 CPB 期间保护心脏组织免受氧化损伤的能力。（c）一些研究报告称，使用去铁胺可改善左心室射血分数和室壁运动评分指数。
本综述表明，去铁胺是一种有效且安全的药物，可用于预防 CPB 后心肌 I/R 损伤。它还强调了需要进行更大规模的试验，以制定关于使用去铁胺治疗 I/R 损伤的潜在策略和指南。
Zotero 插件